Escalating to extrafine single-inhaler triple therapy significantly reduces exacerbations in patients with moderate to severe COPD.
Immunomodulatory approaches such as GRI-0621 (RARβγ agonist targeting iNKT activity) may support alveolar basement membrane repair and provide complementary biology for oral combination regimens.